Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Lysozyme Goat Milk in Stem Cell Transplant
NCT03531281Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human lysozyme goat milk in graft-versus-host disease (GVHD) and Infection (2 arms), sponsored by City of Hope. Primary endpoints: Feasibility of drinking human lysozyme goat milk, Unacceptable toxicity and 2 more. Planned start Dec 2018; status: withdrawn.
02
Drugs
human lysozyme goat milk
03
Conditions
graft-versus-host disease (GVHD)Infection
Beyond the preview
Go deeper on NCT03531281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531281.